Sanofi (NASDAQ:SNY) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its position in Sanofi (NASDAQ:SNYFree Report) by 8.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,610,107 shares of the company’s stock after selling 228,796 shares during the quarter. Envestnet Asset Management Inc. owned about 0.10% of Sanofi worth $129,801,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Dynamic Advisor Solutions LLC acquired a new stake in shares of Sanofi during the fourth quarter worth $2,104,000. Clearbridge Investments LLC lifted its holdings in shares of Sanofi by 8.4% during the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock worth $9,904,000 after purchasing an additional 14,362 shares during the period. Soros Fund Management LLC acquired a new stake in shares of Sanofi during the third quarter worth $11,533,000. Oxbow Advisors LLC acquired a new stake in shares of Sanofi during the fourth quarter worth $4,689,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sanofi by 348.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 32,456 shares of the company’s stock worth $1,614,000 after purchasing an additional 25,213 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Read Our Latest Stock Analysis on Sanofi

Sanofi Stock Down 1.1 %

Shares of NASDAQ:SNY opened at $48.98 on Friday. The stock’s 50-day moving average price is $48.31 and its two-hundred day moving average price is $48.42. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72. The firm has a market cap of $123.91 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 1.54 and a beta of 0.60.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting the consensus estimate of $0.96. The business had revenue of $11.36 billion for the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. On average, research analysts forecast that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were issued a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date was Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 74.37%.

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.